glp-1 obesity drug news Dozens of new drugs are coming: these are the ones to watch Half of GLP-1 users ditch

Both doses of orforglipron lowered blood sugar more than both doses of semaglutide

Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial

Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum)

Geniposide was obtained from Wako Pure Chemical Industries, Ltd (Osaka, Japan)

We provide specific strategies to minimize discomfort during this phase

A comprehensive meta-analysis of eight GLP-1 RA CVOTs revealed several critical findings: 14% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [3] 13% reduction in cardiovascular death [3] 10% reduction in all-cause mortality [3] 11% reduction in hospitalization for heart failure [3] Post-hoc analyzes from LEADER and SUSTAIN-6 revealed that cardiovascular benefits extended across the spectrum of body mass index categories, indicating efficacy regardless of baseline weight [2]